Caloric restriction and exercise “mimetics’’: Ready for prime time?

详细信息    查看全文

• 作者：Christoph Handschin ; ^{christoph.handschin@unibas.ch" class="auth_mail" title="E-mail the corresponding author}
• 关键词：AICAR (PubChem CID 266934) ; Celastrol (PubChem CID 122724) ; (&minus ; )-Epicatechin (PubChem CID 72276) ; GSK4716 (PubChem CID 5399376) ; GW1516 (PubChem ID 9803963) ; Metformin (PubChem CID 4091) ; Nicotinamide riboside (PubChem CID 439924) ; Rapamycin (PubChem CID 5040) ; Resveratrol (PubChem CID 445154) ; SR9009 (PubChem ID 57394020) ; SRT1720 (PubChem ID 25232708) ; Ursolic acid (PubChem CID 64945)
• 刊名：Pharmacological Research
• 出版年：2016
• 出版时间：January 2016
• 年：2016
• 卷：103
• 期：Complete
• 页码：158-166
• 全文大小：1215 K

文摘

Exercise and diet are powerful interventions to prevent and ameliorate various pathologies. The development of pharmacological agents that confer exercise- or caloric restriction-like phenotypic effects is thus an appealing therapeutic strategy in diseases or even when used as life-style and longevity drugs. Such so-called exercise or caloric restriction “mimetics” have so far mostly been described in pre-clinical, experimental settings with limited translation into humans. Interestingly, many of these compounds activate related signaling pathways, most often postulated to act on the common downstream effector peroxisome proliferator-activated receptor γ coactivator 1α (PGC-1α) in skeletal muscle. In this review, resveratrol and other exercise- and caloric restriction “mimetics” are discussed with a special focus on feasibility, chances and limitations of using such compounds in patients as well as in healthy individuals.